Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia


Ciftciler R., DEMİROĞLU H. , BÜYÜKAŞIK Y. , ALADAĞ KARAKULAK E. , AKSU S. , HAZNEDAROĞLU İ. C. , ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, ss.177-182, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 19 Konu: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2018.11.016
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Sayfa Sayıları: ss.177-182

Özet

The group of patients with refractory acute myeloid leukemia includes those patients who fail standard induction chemotherapy, who relapse within 6 months after first complete remission, and who have relapsed twice or more. The outcome of these patients is usually very poor, with only a small proportion who can be rescued by allogenic hematopoietic stem cell transplantation. The aim of this study is to evaluate the efficacy and feasibility of allogenic hematopoietic stem cell transplantation in patients with refractory acute myeloid leukemia.